Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Open original source
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Open original source